FHLT
Future Health ESG Corp. [FHLT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FHLT Stock Summary
In the News
FHLT Financial details
Company Rating
Sell
Market Cap
76.03M
Income
-48.43K
Revenue
0
Book val./share
-0.03
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
74.04
Forward P/E
-
PEG
-1.89
P/S
-
P/B
10.12
P/C
635
P/FCF
-82.48
Quick Ratio
0.2
Current Ratio
0.24
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-396%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-188.12%
-
-
-
-
SMA20
9.09%
SMA50
9.09%
SMA100
9.09%
Inst Own
36.89%
Inst Trans
0.65%
ROA
6%
ROE
14%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
165%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.97-15.05
52W High
-15.33%
52W Low
+41.11%
RSI
71
Rel Volume
9.61
Avg Volume
2.14K
Volume
20.55K
Perf Week
17.81%
Perf Month
12.19%
Perf Quarter
-
Perf Half Y
20.38%
-
-
-
-
Beta
-0.049
-
-
Volatility
0.34%, 0.79%
Prev Close
-0.83%
Price
12.7
Change
3.25%
FHLT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | |
| Net income per share | -0.01 | 0 | -0.01 | |
| Operating cash flow per share | -0.01 | -0.05 | -0.11 | |
| Free cash flow per share | -0.01 | -0.05 | -0.11 | |
| Cash per share | 0.06 | 0.03 | 0.02 | |
| Book value per share | 7.74 | 0.29 | -0.03 | |
| Tangible book value per share | 7.74 | 0.29 | -0.03 | |
| Share holders equity per share | 7.74 | 0.29 | -0.03 | |
| Interest debt per share | 0 | 0 | 0 | |
| Market cap | 243.75M | 244.35M | 70.29M | |
| Enterprise value | 242.3M | 243.51M | 70.17M | |
| P/E ratio | -1.35K | 4.09K | -1.45K | |
| Price to sales ratio | 0 | 0 | 0 | |
| POCF ratio | -998.99 | -194.33 | -97.91 | |
| PFCF ratio | -998.99 | -194.33 | -97.91 | |
| P/B Ratio | 1.26 | 35.19 | -332.28 | |
| PTB ratio | 1.26 | 35.19 | -332.28 | |
| EV to sales | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.29K | -48.61 | -103.41 | |
| EV to operating cash flow | -993.06 | -193.67 | -97.74 | |
| EV to free cash flow | -993.06 | -193.67 | -97.74 | |
| Earnings yield | 0 | 0 | 0 | |
| Free cash flow yield | 0 | -0.01 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | |
| Net debt to EBITDA | 7.72 | 0.17 | 0.18 | |
| Current ratio | 12.56 | 0.7 | 0.02 | |
| Interest coverage | 29.3 | -233.01 | 0 | |
| Income quality | 1.35 | -21.02 | 14.83 | |
| Dividend Yield | 0 | 0.01 | 0 | |
| Payout ratio | -0.02 | 43.5 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | |
| Graham number | 1.12 | 0.13 | 0.07 | |
| ROIC | 0 | -0.1 | -1.47 | |
| Return on tangible assets | 0 | 0 | 0 | |
| Graham Net | -0.31 | -0.39 | -2.63 | |
| Working capital | 1.43M | -388.11K | -8.31M | |
| Tangible asset value | 193.51M | 6.94M | -211.55K | |
| Net current asset value | -7.57M | -9.39M | -17.31M | |
| Invested capital | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | |
| Average payables | 0 | 10.98K | 525.19 | |
| Average inventory | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | |
| ROE | 0 | 0.01 | 0.23 | |
| Capex per share | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.04 | -0.02 | 0.01 | 0.01 | -0.01 | |
| Operating cash flow per share | -0.01 | -0.02 | -0.05 | -0.01 | -0.02 | |
| Free cash flow per share | -0.01 | -0.02 | -0.05 | -0.01 | -0.02 | |
| Cash per share | 0.03 | 0.1 | 0.05 | 0.04 | 0.02 | |
| Book value per share | 0.28 | 1.04 | 1.04 | 1.05 | -0.03 | |
| Tangible book value per share | 0.28 | 1.04 | 1.04 | 1.05 | -0.03 | |
| Share holders equity per share | 0.28 | 1.04 | 1.04 | 1.05 | -0.03 | |
| Interest debt per share | 0 | -0.03 | 0 | 0 | 0 | |
| Market cap | 251.97M | 65.26M | 67.76M | 69.54M | 70.3M | |
| Enterprise value | 251.13M | 64.58M | 67.44M | 69.28M | 70.18M | |
| P/E ratio | 67.01 | -157.15 | 356.85 | 262.28 | -301.1 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -923.45 | -412.29 | -188.86 | -1.11K | -509.05 | |
| PFCF ratio | -923.45 | -412.29 | -188.86 | -1.11K | -509.05 | |
| P/B Ratio | 36.29 | 9.54 | 9.84 | 10 | -332.31 | |
| PTB ratio | 36.29 | 9.54 | 9.84 | 10 | -332.31 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -131.19 | -152.65 | -221.32 | -217.91 | -326.59 | |
| EV to operating cash flow | -920.38 | -408 | -187.96 | -1.1K | -508.19 | |
| EV to free cash flow | -920.38 | -408 | -187.96 | -1.1K | -508.19 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | -0.01 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.44 | 1.61 | 1.05 | 0.81 | 0.56 | |
| Current ratio | 0.7 | 0.54 | 0.32 | 0.24 | 0.02 | |
| Interest coverage | -95 | 1.37 | 0 | 0 | 0 | |
| Income quality | -0.29 | 1.52 | -7.56 | -0.95 | 2.37 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 1.48 | -1.68 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.49 | 0.61 | 0.41 | 0.49 | 0.08 | |
| ROIC | -0.08 | -0.06 | -0.01 | -0.01 | 2.44 | |
| Return on tangible assets | 0.05 | -0.01 | 0 | 0 | 0 | |
| Graham Net | -0.38 | -1.48 | -1.5 | -1.52 | -2.63 | |
| Working capital | -388.11K | -666.54K | -813.7K | -960.16K | -8.31M | |
| Tangible asset value | 6.94M | 6.84M | 6.89M | 6.95M | -211.55K | |
| Net current asset value | -9.39M | -9.67M | -9.81M | -9.96M | -17.31M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 459.09K | 1.1K | 1.13K | 551.97 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.14 | -0.02 | 0.01 | 0.01 | 0.28 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FHLT Frequently Asked Questions
What is Future Health ESG Corp. stock symbol ?
Future Health ESG Corp. is a US stock , located in Dover of De and trading under the symbol FHLT
What is Future Health ESG Corp. stock quote today ?
Future Health ESG Corp. stock price is $12.7 today.
Is Future Health ESG Corp. stock public?
Yes, Future Health ESG Corp. is a publicly traded company.
Company Profile
- Volume Average 2.14K
- Market Capitalization 76.03M
- CEO Ms. Jesvin Kaur
- Headquarters Dover,DE,US
- IPO Date 2021-12-08
-
Website
https://www.fhesg.com 
Future Health ESG Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to pursue an initial business combination opportunity in the smart health technology sector. The company was incorporated in 2021 and is based in Dover, Delaware.
